Oncology continues to dominate global clinical trials, while other disease areas gain momentum.

While oncology and central nervous system (CNS) trials remain the most common areas for clinical drug development, pharma and biotech companies are increasingly testing their metabolic and immunology-focused assets in clinical trials.